An experimental study on the effect of isoniazid on the efficacy, plasma concentration and toxicity of paracetamol in Albino rats

Navdeep Dahiya, Sushil Sharma, Anjan Khadka, Dick S. Brashier, A. K. Gupta, A. K. Sharma

Abstract


Background: Paracetamol is used for symptomatic treatment of fever and pain with isoniazid and other anti-tubercular drugs in patients of tuberculosis. Literature has conflicting data regarding their interaction. Some studies show that isoniazid increases oxidative metabolism of paracetamol whereas some other suggest that isoniazid has an inhibitory effect. The present study was conducted to find out the possible interaction between paracetamol and isoniazid.

Methods: The study was undertaken on Wistar strain of Albino rats. Group I and Group II animals were treated with paracetamol (500 mg/kg) and the combination of paracetamol (500 mg/kg) and isoniazid (30 mg/kg) respectively for 2 months. Blood samples were taken before and during the study for biochemical and histopathological studies of liver and renal functions and plasma paracetamol concentration was also evaluated.

Results: Isoniazid decreased the plasma paracetamol concentration without affecting its analgesic activity. However, the hepatotoxic and nephrotoxic effects of paracetamol were found to be further aggravated by isoniazid co-administration.

Conclusion: Isoniazid potentiates the hepatotoxic and nephrotoxic effects of paracetamol possibly due to hepatic enzyme induction by isoniazid.


Keywords


Efficacy, Isoniazid, Paracetamol, Toxicity

Full Text:

PDF

References


World Health Organization. Treatment of Tuberculosis: guidelines. 4th Edition. Geneva: WHO; 2009.

Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton, FL: CRC Press; 1991: 13-57.

Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med. 2010;16(3):186-93.

Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:w13080.

James L, Roberts D. Isoniazid hepatotoxicity: progress in understanding the immunologic component. Hepatology. 2014;59(3):746-8.

Twycross R, Pace V, Mihalyo M, Wilcock A. Acetaminophen (paracetamol). J Pain Symptom Manage. 2013;46(5):747-55.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007;51(7):2329-36.

Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25(2):111-33.

Crippin JS. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol. 1993;88(4):590-2.

Bennett S. Pharmacology of paracetamol and prescribing considerations. Nurse Prescr. 2013;11(1):28-33.

Epstein MM, Nelson SD, Slattery JT, Kalhorn TF, Wall RA, Wright JM. Inhibition of the metabolism of paracetamol by isoniazid. Br J Clin Pharmacol. 1991;31(2):139-42.

Nicod L, Viollon C, Regnier A, Jacqueson A, Richert L. Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Hum Exp Toxicol. 1997;16(1):28-34.

Paget GE, Barnes AL. Toxicity tests. In: Laurence DR, Bacharach AL, editors. Evaluation of Drug Activities: pharmacometerics. London, New York: Academic Press; 1964: 135-66.

Glyn JP, Kendal SE. Paracetamol measurement. Lancet. 1975;1(7916):1147-8.

Patel DK, Shah KH, Tank MK. Evaluation of hepatoprotective activity of polyherbal formulation in paracetamol induced hepatotoxicity in rats. J Pharm Sci Rev Res. 2013;22(1):134-9.

Andrade RJ, Lucena MI, Melgarejo F, García-Escaño MD. Hepatotoxicity caused by isoniazid or by paracetamol. Gastroenterol Hepatol. 1998;21(6):314-5.

Chien JY, Peter RM, Nolan CM, Wartell C, Slattery JT, Nelson SD, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther. 1997;61(1):24-34.